Medizinische Universitaet Graz
Welcome,         Profile    Billing    Logout  
 87 Trials 
108 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Petru, Edgar
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Recruiting
3
650
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
10/24
06/27
MATAO, NCT04111978: MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer

Recruiting
3
540
Europe
Letrozole 2.5mg, Femara, Placebo
Swiss GO Trial Group, AGO Study Group, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Reliable Cancer Therapies, Krebsliga Schweiz, Stiftung Guido Feger, Hoffmann-La Roche, Helsana AG, Novartis Pharmaceuticals, Anticancer Fund, Belgium
Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma
10/25
10/30
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT05797831: Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Recruiting
2/3
268
Europe, Canada, US, RoW
Navtemadlin, KRT-232, Navtemadlin Placebo
Kartos Therapeutics, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Endometrial Cancer
08/25
07/27
Beck, Andrea
MAMOC, NCT04227522: Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

Active, not recruiting
3
190
Europe
Rucaparib, Placebos
North Eastern German Society of Gynaecological Oncology, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Clovis Oncology, Inc.
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Clear Cell Carcinoma
12/23
01/25
PALISADE, NCT05089084 / 2021-003680-10: Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Active, not recruiting
3
75
Europe, Canada, Japan, US, RoW
Plozasiran, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Familial Chylomicronemia
04/24
04/26
Topiak, Hermann
PALISADE, NCT05089084 / 2021-003680-10: Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Active, not recruiting
3
75
Europe, Canada, Japan, US, RoW
Plozasiran, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Familial Chylomicronemia
04/24
04/26
 

Download Options